1-3 of 3
Inés M. Macias-Pérez, PhD
Close
Sort by
Journal Articles

A Phase II Trial of Ofatumumab for Older Patients and Patients Who Refuse Fludarabine-Based Regimens with Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma,

Ian W. Flinn, MD, PhD, William N. Harwin, MD, Inés M. Macias-Pérez, PhD, Patrick S. Tucker, MS, David M. Waterhouse, MD, Steven W. Papish, MD, Jeffrey A. Jones, MD, MPH, John D. Hainsworth, MD, John C. Byrd, MD
Journal: Blood
Blood (2011) 118 (21): 3912.
https://doi.org/10.1182/blood.V118.21.3912.3912
Published: 2011
Journal Articles

A Phase II Trial of Combined Bendamustine, Bortezomib and Dexamethasone in Newly Diagnosed Multiple Myeloma (MM) Patients Who Are Not Candidates for High-Dose Chemotherapy: Results of a Planned Interim Safety Analysis

Jesus G. Berdeja, MD, Daniel R. Couriel, MD, Patrick Murphy, MD, Ralph V. Boccia, MD, Victor Priego, MD, John D. Hainsworth, MD, Inés M. Macias-Pérez, PhD, Ian W. Flinn, MD, PhD
Journal: Blood
Blood (2011) 118 (21): 2943.
https://doi.org/10.1182/blood.V118.21.2943.2943
Published: 2011
Journal Articles

Preliminary Results of a Phase II Trial of Panobinostat (LBH589) In Refractory Myelodysplastic Syndromes (MDS) Patients

Ian W. Flinn, MD, PhD, Evan Lang, MD, Eric Raefsky, MD, Ralph Boccia, MD, Inés M. Macias-Pérez, PhD, Howard A. Burris, III, MD, John D. Hainsworth, MD
Journal: Blood
Blood (2010) 116 (21): 4015.
https://doi.org/10.1182/blood.V116.21.4015.4015
Published: 2010